NRSN
NeuroSense Therapeutics Ltd.
NasdaqCMUSDEQUITY
DELAYED
Last price
0.38
▲ 0.03 (7.33%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
0.35
Prev close
0.35
Day high
0.39
Day low
0.35
Volume
127.36K
Market cap
—
P/E (TTM)
—
52W range
0.25 – 1.98
Day trading desk
Gap from prior close
+0.11%
Prior close 0.35
VWAP
0.37
+2.29% from price
Relative volume
—
—
Session range
13.53%
0.35 – 0.40
Position in range
54%
Mid range
ATR (14D)
0.07
19.58% of price
Prior day high
0.40
PDH
Prior day low
0.35
PDL
Bid / ask spread
—
Quote not published
Session volume
147.79K
Shares traded
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-17.00%
-15.6%
1M
-42.60%
-46.3%
3M
-51.36%
-54.5%
6M
-58.41%
-69.5%
YTD
-51.11%
-63.4%
1Y
-68.05%
-88.1%
3Y
-58.68%
-132.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on NRSN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $6.23M | $5.70M | $7.27M | $5.59M | +9.3% |
| Selling, general & admin | $4.86M | $4.20M | $4.78M | $4.97M | +15.6% |
| Total operating expense | $11.09M | $9.90M | $12.05M | $10.55M | +11.9% |
| Operating income | -$11.09M | -$9.90M | -$12.05M | -$10.55M | -11.9% |
| Net interest income | $7.00K | -$309.00K | -$270.00K | $84.00K | +102.3% |
| Pre-tax income | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Net income | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Net income to common | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Basic EPS | -0.44 | -0.54 | -0.74 | -0.91 | +18.5% |
| Diluted EPS | -0.44 | -0.54 | -0.74 | -0.91 | +18.5% |
| EBIT | -$11.09M | -$9.90M | -$12.05M | -$10.55M | -11.9% |
| EBITDA | -$11.07M | -$9.88M | -$12.03M | -$10.54M | -12.0% |
| Basic shares | 25.48M | 18.91M | 13.64M | 11.50M | +34.8% |
| Diluted shares | 25.48M | 18.91M | 13.64M | 11.50M | +34.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $166.00K | $3.38M | $2.64M | $3.54M | -95.1% |
| Cash & short-term investments | $166.00K | $3.38M | $2.64M | $7.09M | -95.1% |
| Total current assets | $778.00K | $4.40M | $2.92M | $7.38M | -82.3% |
| Property, plant & equipment | $228.00K | $150.00K | $247.00K | $306.00K | +52.0% |
| Total assets | $1.03M | $4.58M | $3.19M | $7.71M | -77.5% |
| Total current liabilities | $2.52M | $1.99M | $3.46M | $1.73M | +26.3% |
| Total debt | $170.00K | $73.00K | $142.00K | $211.00K | +132.9% |
| Total liabilities | $2.59M | $1.99M | $4.94M | $2.09M | +29.9% |
| Retained earnings | -$47.78M | -$36.66M | -$26.12M | -$20.79M | -30.3% |
| Shareholder equity | -$1.56M | $2.58M | -$1.76M | $5.62M | -160.4% |
| Working capital | -$1.74M | $2.41M | -$543.00K | $5.66M | -172.1% |
| Net tangible assets | -$1.56M | $2.58M | -$1.76M | $5.62M | -160.4% |
| Shares issued | 32.56M | 23.23M | 15.38M | 11.78M | +40.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$11.13M | -$10.21M | -$10.11M | -$10.49M | -9.0% |
| Depreciation & amortisation | $16.00K | $22.00K | $21.00K | $12.00K | -27.3% |
| Stock-based compensation | $2.14M | $557.00K | $1.54M | $1.73M | +284.2% |
| Change in working capital | $1.34M | -$781.00K | $1.91M | $1.09M | +272.1% |
| Operating cash flow | -$7.67M | -$10.13M | -$8.35M | -$7.62M | +24.3% |
| Capital expenditure | -$8.00K | -$3.00K | -$29.00K | -$70.00K | -166.7% |
| Investing cash flow | -$8.00K | $1.00K | $3.47M | -$3.59M | -900.0% |
| Financing cash flow | $4.43M | $10.91M | $3.98M | $3.77M | -59.4% |
| Free cash flow | -$7.68M | -$10.14M | -$8.38M | -$7.69M | +24.3% |
| End cash position | $166.00K | $3.38M | $2.64M | $3.54M | -95.1% |
| Line item | 2024-12-31 | YoY |
|---|---|---|
| Total revenue | $0 | |
| Operating revenue | $0 | |
| Research & development | $1.09M | |
| Selling, general & admin | $685.00K | |
| Total operating expense | $1.77M | |
| Operating income | -$1.77M | |
| Net interest income | -$31.00K | |
| Pre-tax income | -$1.80M | |
| Net income | -$1.80M | |
| Net income to common | -$1.80M | |
| EBIT | -$1.77M | |
| EBITDA | -$1.77M |
| Line item | 2025-12-31 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|
| Cash & equivalents | $166.00K | $666.00K | $3.38M | -75.1% |
| Cash & short-term investments | $166.00K | $666.00K | $3.38M | -75.1% |
| Total current assets | $778.00K | $1.56M | $4.40M | -50.0% |
| Property, plant & equipment | $228.00K | $105.00K | $150.00K | +117.1% |
| Total assets | $1.03M | $1.68M | $4.58M | -39.0% |
| Total current liabilities | $2.52M | $2.20M | $1.99M | +14.2% |
| Total debt | $170.00K | — | $73.00K | — |
| Total liabilities | $2.59M | $2.20M | $1.99M | +17.5% |
| Retained earnings | -$47.78M | -$41.37M | -$36.66M | -15.5% |
| Shareholder equity | -$1.56M | -$519.00K | $2.58M | -200.6% |
| Working capital | -$1.74M | -$647.00K | $2.41M | -168.6% |
| Net tangible assets | -$1.56M | -$519.00K | $2.58M | -200.6% |
| Shares issued | 32.56M | 24.60M | 23.23M | +32.3% |
No filings published for this symbol yet.
Newly listed companies often have nothing on file until their first annual report.
Newly listed companies often have nothing on file until their first annual report.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.43
-11.73% from price
SMA 20
0.47
-19.65% from price
SMA 50
0.62
-39.05% from price
SMA 100
0.70
-46.50% from price
SMA 200
0.82
-53.87% from price
EMA 12
0.43
-12.87% from price
EMA 26
0.50
-25.06% from price
EMA 50
0.58
-35.42% from price
RSI (14)
28.4
Oversold
MACD (12,26,9)
-0.07
Hist -0.01
ATR (14)
0.07
19.59% of price
Realised vol 30D
87.6%
Annualised
Bollinger upper
0.59
20, 2σ
Bollinger lower
0.35
20, 2σ
50 / 200 cross
Death
0.62 vs 0.82
Trend bias
Below 200
-53.87%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.00
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
87.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-74.3%
Peak to trough
Max drawdown 5Y
-94.4%
Peak to trough
ATR 14
0.07
19.59% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
NeuroSense Issues CEO Letter to Shareholders
PR Newswire · 10d ago
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
PR Newswire · 17d ago
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS
PR Newswire · 32d ago
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
PR Newswire · 48d ago
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint
MT Newswires · 55d ago
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
PR Newswire · 55d ago
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
PR Newswire · 59d ago
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
PR Newswire · 62d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.